TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05692167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical dexmedetomidine
Description: Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reginal dexmedetomidine
Description: Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
Study: NCT06440850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study: NCT05681819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: Multiple-ascending Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1707 placebo
Description: Multiple-ascending Dose
Study: NCT06467201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSHN001126 150mg
Description: 6 subjects will receive single oral dose of 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSHN001126 300mg
Description: 6 subjects will receive single oral dose of 300mg
Study: NCT05320185

Intervention type: DEVICE
Intervention: RuiXin-CoronaryAI software
Description: RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
Study: NCT06467201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSHN001126 600mg
Description: 6 subjects will receive single oral dose of 600mg
Study: NCT04752319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will be applied for 10 to 20 minutes per session for multiple sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: EStim will be applied for 10 to 20 minutes per session for multiple sessions
Study: NCT06115785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
Study: NCT06258564

Intervention type: BIOLOGICAL
Intervention: vaccination against human papillomavirus infection (HPV vaccination)
Description: Women with or without HPV vaccination before or after excision
Study: NCT06468826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Oral capsules
Study: NCT04139304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT06264154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Description: All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarettes
Description: All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarettes
Description: All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.
Study: NCT04369326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Based TPT Initiation
Description: Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
Study: NCT06549985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEEPS
Description: Participants will participate in the PEEPS program in addition to usual care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive an educational handout on endometriosis in addition to usual care.
Study: NCT06346119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day
Description: Patients who will be included in this arm will receive massage twice a day of the head (10 minutes), feet (10 minutes) and hands (10 minutes)
Study: NCT05249660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue release technique
Description: Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Instrument assisted soft tissue mobilization
Description: Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
Study: NCT05883423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FPCMP-Old Age
Description: 1. Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~2. Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)
Study: NCT05264727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinisol 15%
Description: Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
Study: NCT05663229

Intervention type: DEVICE
Intervention: Ankle foot orthosis
Description: We evaluate the difference of with or without ankle foot orthosis
Study: NCT05484557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: treatment for 6 to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium
Description: treatment for 6 to 12 weeks
Study: NCT05200338

Intervention type: DRUG
Group type: OTHER
Intervention: Engerix-B
Description: Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Engerix-B
Description: Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Engerix-B
Description: Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Engerix-B
Description: Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Engerix-B
Description: Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
Study: NCT04913116

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of antigen tests with RT-PCR as reference method
Description: Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of antigen tests with RT-PCR as reference method
Description: Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
Study: NCT05694611

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
Study: NCT05949892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Health Belief Model-Based Intervention
Description: A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Health Belief Model-Based Intervention
Description: A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Health Belief Model-Based Intervention
Description: A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Health Belief Model-Based Intervention
Description: A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Health Belief Model-Based Intervention
Description: A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
Study: NCT05051228

Intervention type: DEVICE
Intervention: CardioFlux
Description: Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
Study: NCT06560892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine injection
Description: patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine injection
Description: patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
Study: NCT06112275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
Study: NCT06440850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT06352970

Intervention type: OTHER
Intervention: TB infection
Description: Outcomes will be compared with regard to result of interferon-gamma release assay test for TB infection
Study: NCT05475002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care empowerment program
Description: dementia care e-books, dementia virtual reality activity and family support group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dementia education
Description: dementia education manual and family support group
Study: NCT06440850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo I-123 diagnostic scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I-131 Uptake Test
Description: Undergo I-131 whole body scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Thyrotropin Alfa
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo neck ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study: NCT05885126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MANDALA TECHNIQUE
Description: The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
Study: NCT04771273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06529809

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated external beam radiation
Description: Central pelvis (20 Gy in 10 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided brachytherapy
Description: HDR boost 7.3 Gy x 6 fractions
Study: NCT06526585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyclic Sighing Breathing
Description: Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing practice during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the cyclic sighing during the 2 MRI assessments.~The cyclic sighing protocol consists of a breathing pattern that involves inhaling deeply, starting abdominally, inhaling through the nose until lungs feel comfortably filled, immediately followed by a second shorter inhale, also through the nose, to maximally inflate the lungs. Then participants are instructed to slowly exhale through the mouth until their lungs feel empty. This cycle is repeated for 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Box Breathing
Description: Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the box breathing during the 2 MRI assessments.~The CO2 tolerance test is done at baseline to determine their comfort level with the duration of each side of the box during box breathing.~The box breathing protocol consists of a four-part breathing technique. The practice involves breathing through the nose in four equally timed parts: inhale, hold, exhale, and hold again, forming a 'box' of breaths (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold).This cycle is repeated for 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Participants are instructed to sit comfortably or lie down during the 28 day at home practice (Participants will be lying down in the scanner during the 2 MRIs). Then participants are asked to look up, slowly close their eyes, take a deep breath, slowly exhale, and let their body float, and then to imagine floating in a bath, a lake, a hot tub, or floating in space. Participants are then asked to picture an imaginary screen and visualize a place where it would naturally feel comfortable and relaxed. The participants then divide the screen in half and picture on the left side one thing that is causing them stress, with the rule that no matter what the participant picture, to keep their body comfortable and relaxed. Then on the right side of the screen the participants are asked to picture one thing that can be done about the problem on the left. At the end the participant will be guided to come out of the state of hypnosis. This exercise will take 10 minutes.
Study: NCT06210893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The cricoid cartilage is located.
Description: The cricoid cartilage is located.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The cricoid cartilage is located.
Description: The cricoid cartilage is located.
Study: NCT06041139

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance, intermediate and near visual acuity.
Study: NCT06097338

Intervention type: PROCEDURE
Intervention: bariatric surgery (BS)
Description: bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
Study: NCT05826808

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
Study: NCT05548309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen face mask
Description: Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
Study: NCT05816720

Intervention type: DRUG
Intervention: Lutetium-177 DOTATATE
Description: Intravenous administration

Intervention type: DRUG
Intervention: Lutetium-177 DOTATATE
Description: Intravenous administration

Intervention type: DRUG
Intervention: Lutetium-177 DOTATATE
Description: Intravenous administration
Study: NCT05122871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scape Room
Description: Practical training through scape-room with simulator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation
Description: Practical training through simulator